Scilex Holding (SCLX) Net Income towards Common Stockholders (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Net Income towards Common Stockholders of -$43.3 million for Q1 2026, down 65.91% year-over-year from -$126.9 million in Q1 2025, and down 30.68% on a QoQ basis from -$33.1 million in Q4 2025.
Scilex Holding (SCLX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$43.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 65.91% year-over-year to -$43.3 million; the TTM figure through Mar 2026 stood at -$419.7 million (down 403.18% YoY), while the FY2025 annual figure was -$402.5 million, down 392.63% from the prior year.
- Net Income towards Common Stockholders came in at -$43.3 million for Q1 2026 at Scilex Holding, down from -$33.1 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $21.5 million in Q3 2022, with the low at -$257.2 million in Q3 2025.
- Average Net Income towards Common Stockholders over 5 years is -$42.2 million, with a median of -$26.1 million recorded in 2025.
- The largest YoY upside for Net Income towards Common Stockholders was 7736.6% in 2022 against a maximum downside of 10688.09% in 2022.
- Year by year, Net Income towards Common Stockholders stood at -$17.9 million in 2022, then decreased by 19.66% to -$21.4 million in 2023, then gained by 28.25% to -$15.4 million in 2024, then slumped by 115.64% to -$33.1 million in 2025, then sank by 30.68% to -$43.3 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$43.3 million, -$33.1 million, and -$257.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 47.33 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 1.65 |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -43.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.27 Mn |
| Dec 31, 2025 | -33.11 Mn |
| Sep 30, 2025 | -257.23 Mn |
| Jun 30, 2025 | -86.06 Mn |
| Mar 31, 2025 | -26.08 Mn |
| Dec 31, 2024 | -15.36 Mn |
| Sep 30, 2024 | -4.39 Mn |
| Jun 30, 2024 | -37.58 Mn |
| Mar 31, 2024 | -24.38 Mn |
| Dec 31, 2023 | -21.40 Mn |
| Sep 30, 2023 | -88.17 Mn |
| Jun 30, 2023 | -26.65 Mn |
| Mar 31, 2023 | -30.75 Mn |
| Dec 31, 2022 | -17.88 Mn |
| Sep 30, 2022 | 21.50 Mn |
| Jun 30, 2022 | -17.84 Mn |
| Mar 31, 2022 | -9.14 Mn |
| Dec 31, 2021 | -35.26 Mn |
| Sep 30, 2021 | -281,552.00 |
| Jun 30, 2021 | -165,349.00 |